LDN shows biologically plausible anti-inflammatory effects via glial cells and opioid receptors, and small clinical studies in fibromyalgia, Crohn's disease, and multiple sclerosis report subjective improvements. The research is still at an early stage: there are no large randomised trials, study groups are small, and objective outcome measures have rarely been assessed. The safety profile looks favourable in the available literature, but long-term data are lacking and use is off-label.
Low-dose naltrexone (LDN) is attracting attention as an anti-inflammatory agent, but the vast majority of available research consists of small studies, cell experiments, and animal studies. No large randomised clinical trials have yet convincingly demonstrated its effect in humans. That does not mean there is nothing to report, but the findings should be read as early, preliminary signals.
The best-described mechanism is that LDN acts on glial cells, the supporting cells in the brain and spinal cord that also play a role in inflammation. In cell studies and small clinical studies, LDN reduces the release of inflammatory substances from those glial cells. It has also been proposed that LDN slows the proliferation of certain white blood cells (T and B cells) and blocks an inflammatory receptor called TLR4. These are plausible mechanisms, but they have not yet been definitively proven in large human studies.
The most concrete clinical signal in humans comes from small controlled studies in fibromyalgia: participants reported less pain and a better quality of life compared with placebo. Small studies with positive subjective outcomes also exist for Crohn's disease and multiple sclerosis. The word 'subjective' is relevant here: objective measures such as disease activity on scans or blood values have barely been investigated. The groups were always small, so robust conclusions are not yet possible.
For two newer applications, the signals are even more preliminary. A retrospective study in 59 Long COVID patients found less fatigue and better sleep with LDN use, but there was no randomised control group. A theoretical commentary piece suggested that LDN could reduce blood-clotting problems in COVID-19 through anti-inflammatory action, but there are no clinical data whatsoever to support this. In cell and mouse studies, LDN also reduced inflammation and insulin resistance caused by excessive insulin levels, via a specific molecular pathway (SIRT1/NF-κB), but this too has not yet been tested in humans.
On the safety front, the picture is relatively reassuring: several reviews report that LDN is well tolerated in the conditions studied and that serious side effects have not been reported in the available literature. Nevertheless, long-term safety data in large groups of people are not yet available. Furthermore, LDN for these applications constitutes off-label use, meaning that doctors prescribe it outside officially approved indications. Consulting a doctor is therefore essential before anyone considers this.
Evidence based on: preclinical research (cell and animal models), narrative reviews, and small clinical studies (n=59 for Long COVID; several prospective trials for fibromyalgia). No large RCTs or meta-analyses available as direct sources. PMIDs: 32845365, 29885638, 29377216, 37021443, 32943552, 37804660, 35179184, 32074159.